ulipristal acetátu - search_results

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

ella- ulipristal acetate tablet

a-s medication solutions - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s. background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

ella- ulipristal acetate tablet

rpk pharmaceuticals, inc. - ulipristal acetate (unii: yf7v70n02b) (ulipristal - unii:6j5j15q2x8) - ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see dosage and administration (2.1)] . e lla is not intended for routine use as a contraceptive. ella is contraindicated for use in the case of known or suspected pregnancy [see use in specific populations (8.1)]. risk summary ella is contraindicated for use during an existing or suspected pregnancy. no signal of concern regarding pregnancy complications was found in postmarketing studies [see data ]. isolated cases of major malformations in ella- exposed pregnancies were identified; however, the data are not sufficient to determine a risk for birth defects with inadvertent use of ella during pregnancy. miscarriage was reported in 14% of the known pregnancy outcomes; a rate that is similar to the u.s. background rate for miscarriage. in the u.s. general population, the estimated background risk of major birth defects and